In new research, Dr. Karen Anderson and her colleagues at the Biodesign Institute explore sophisticated new methods for screening for oropharyngeal cancer, which has previously evaded early detection.
Building critical early detection tools
When it comes to treating disease, time is of the essence.
“Study after study after study have demonstrated that the earlier we detect the disease, the better opportunity we have to treat it, and potentially even cure it,” says Dr. Joshua LaBaer, executive director of ASU’s Biodesign Institute.
ASU’s Biodesign Institute has developed tools to detect breast cancer, ovarian cancer and HPV early, during the key stages where the diseases are most treatable. These promising breakthroughs will not only improve outcomes and survivability but will also reduce the costs associated with late-stage cancer detection and treatment.
Today, the Biodesign Institute is hard at work to identify blood-based biomarkers in a number of cancers, which will improve both diagnostic and treatment capabilities. These lifesaving discoveries won’t stay at ASU — we share the benefits of our work with people around the world.